In news

On May 16th, the organization of the American Society of Clinical Oncology (ASCO) confirmed to the company the digital publication of its abstract on the comparison of its CLART® ALK · ROS1 kit for the detection of mutations in oncogenes for cancer patients of non-small cell lung.

The study is a comparison between the IHC, FISH and CLART techniques on the rearrangement of the ALK and ROS1 genes. In conclusion CLART has a concordance of 96.5% with the techniques compared. Its sensitivity and specificity is 100%, resulting in an effective and accurate technique as an alternative to FISH / IHC for the detection of the rearrangements known in EML4-ALK and ROS1.

Abstract completo: